Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 5/20 | 0.72 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.72 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | GRM8 | O00222 | 2/20 | 0.72 |
| ▸ | GRM6 | O15303 | 2/20 | 0.72 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.72 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.72 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.72 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.72 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.72 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.72 |
| ▸ | GSR | P00390 | 1/20 | 0.72 |
| ▸ | GRM5 | P41594 | 1/20 | 0.72 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.72 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.72 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.72 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamic Acid SCHEMBL5614072 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| D-Glutamate SCHEMBL9176409 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL6130437 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL24357 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| D-Glutamate SCHEMBL3512077 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| D-Glutamate SCHEMBL19876607 | 0.96 | SLC1A3 (0.67) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL17926909 | 0.96 | SLC1A3 (0.67) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL1365479 | 0.96 | SLC1A3 (0.67) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL429944 | 0.94 | SLC1A3 (0.64) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| D-Glutamate SCHEMBL21410037 | 0.94 | SLC1A3 (0.64) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258190-B2 | Encapsulated contrast agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2152320-A2 | ENCAPSULATED CONTRAST AGENTS | Intezyne Technologies Incorporated (US) | 2010-02-17 | — | — | EP | claimed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | claimed |
| WO-2008134734-A2 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| US-8258190-B2 | Encapsulated contrast agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2283063-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | Intezyne Technologies Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2152320-A2 | ENCAPSULATED CONTRAST AGENTS | Intezyne Technologies Incorporated (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090286938-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009134984-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | INTEZYNE TECHNOLGIES INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008134734-A2 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286938-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | PFAS, GFPT1, PFKFB4 | SLC1A3 282/4885SLC1A2 803/4885SLC1A1 419/4885 |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | LIPA, LPXN, CD47 | SLC1A3 3317/4885SLC1A2 3748/4885SLC1A1 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.